Reset filter
Keywords
Venous Thromboembolism ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

54 Search results.
Relevance Rating New first Old first

Eligibility Symptomatic Venous Thromboembolism NCT01567917

- 1/22/19 - 1 form, 2 itemgroups, 8 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Incidence of Venous Thromboembolism Following Surgery in Patients With Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01567917

Eligibility Venous Thromboembolism NCT01119261

- 1/4/16 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol; ODM derived from: https://clinicaltrials.gov/show/NCT01119261

Eligibility Venous Thromboembolism Warfarin NCT01119300

- 10/10/18 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin; ODM derived from: https://clinicaltrials.gov/show/NCT01119300 Sponsor: Utrecht Institute for Pharmaceutical Sciences Collaborators: Utrecht University Leiden University Medical Center Erasmus Medical Center University of Ulm Newcastle University University of Liverpool LGC Limited Uppsala University Democritus University of Thrace Elisabethinen Hospital Information provided by (Responsible Party): Anke-Hilse Maitland-van der Zee, Utrecht Institute for Pharmaceutical Sciences Principal Investigator: Munir Pirmohamed, MD PhD University of Liverpool

Eligibility Venous Thromboembolism (VTE) Phenprocoumon NCT01119274

- 10/10/18 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon; ODM derived from: https://clinicaltrials.gov/show/NCT01119274 Sponsor: Utrecht Institute for Pharmaceutical Sciences Collaborators: Utrecht University Leiden University Medical Center Erasmus Medical Center University of Ulm Newcastle University University of Liverpool LGC Limited Uppsala University Democritus University of Thrace Elisabethinen Hospital Information provided by (Responsible Party): Anke-Hilse Maitland-van der Zee, Utrecht Institute for Pharmaceutical Sciences

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Unscheduled Assessment of Symptomatic DVT

- 10/22/18 - 1 form, 4 itemgroups, 18 items, 1 language
Itemgroups: Deep Vein Thrombosis; Evaluation, Ultrasonography, Venography, Deep Vein Thrombosis, Pharmaceutical Preparations
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Visit 00

- 10/1/18 - 1 form, 7 itemgroups, 34 items, 1 language
Itemgroups: Demography, Vital Signs, Pregnancy Test, Medical History; Risk Factors, Venous Thromboembolism, Medical History; History of surgical procedures, Hematology finding, Biochemistry
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - SAE Complementary Information Form

- 8/28/18 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Serious Adverse Event, Serious Adverse Event; Follow-Up
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Unusual Bleeding Form

- 8/28/18 - 1 form, 1 itemgroup, 5 items, 1 language
Itemgroup: Hemorrhage; Unusual
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - End of Treatment/End of Study

- 8/28/18 - 1 form, 2 itemgroups, 5 items, 1 language
Itemgroups: Therapeutic Procedure; End, Clinical Research; End
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Medication Record

- 8/28/18 - 1 form, 1 itemgroup, 8 items, 1 language
Itemgroup: Medication Summary
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Blood Transfusion Record

- 8/28/18 - 1 form, 2 itemgroups, 8 items, 1 language
Itemgroups: Pre-operative Blood Donation, Blood Transfusion Record
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Unscheduled Laboratory Tests

- 8/28/18 - 1 form, 1 itemgroup, 6 items, 1 language
Itemgroup: Laboratory Procedures, Unscheduled
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial